Board of Trustees of the University of Arkansas

Suresh Kumar Thallapuranam

David S McNabb

Srinivas Jayanthi

Ralph L Henry

Kartik Balachandran

Alicia Brown

Jacqueline Morris

Joshua Sakon

Robert Beitle

Kyle Quinn

Jingyi Chen

Bhanuprasanth Koppolu

David A Zaharoff

Olivia Kolenc

Ravi Kumar Gundampati

Ngoc Lam

Rebecca Kerr

Isabelle Niyonshuti

Yazan Hussien Akkam

Duy Tu Nguyen

Shilpi Agarwal

Tengjiao Wang

Bhanu Prasanth Koppolu

Jake Jones

Rudra Palash Mukherjee

Sean C Smith

Engineered FGF1 and FGF2 polypeptides, polynucleotides encoding these polypeptides and DNA constructs, vectors and compositions including these engineered polypeptides are provided herein. The engineered FGF1 and FGF2 polypeptides are more stable than their wild-type counterparts and may be more effective at treating a variety of conditions that FGF1 and FGF2 are useful for treating such as wound healing.

Engineered FGF1 and FGF2 compositions and methods of use thereof

Photoluminescent proteins resistant to protein cleavage reagents are described herein. In being resistant to cleavage reagents, such photoluminesncent proteins can reduce the number of digestion or cleavage products, thereby simplifying quantification and purification of recombinant protein compositions. In some embodiments, a photoluminescent protein described herein comprises an amino acid sequence having an absence of internal methionine residues.

Cleavage resistant photoluminescent proteins and applications thereof

The present invention relates to the development of stable mutants of FGF-1 and FGF-2. In particular, it relates to novel engineered FGF-1 and FGF-2 polypeptides as well as polynucleotides, DNA constructs, and vectors encoding such polypeptides. In another aspect, pharmaceutical compositions and hydrogels including the disclosed polypeptides, polynucleotides, DNA constructs, and vectors are provided. In a still further aspect, methods of treating conditions using the compositions disclosed herein are provided.

Engineered FGF compositions and methods of use thereof

In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine.

Heparin affinity tag and application thereof

Heparin affinity tag and applications thereof

Compositions with antifungal activity and methods of using such compositions are provided herein. In particular the compositions are peptides of SEQ ID NO: 1 and variations thereof. The peptides may contain L or D amino acids and may be circularized, dimerized or otherwise modified to make the compositions resistant to proteolysis. The compositions may be used to inhibit microbial growth and in particular fungal growth.

Peptides with antifungal activity and methods of using the peptides

Growing community of inventors

Fayetteville, AR, United States of America

Suresh Kumar Thallapuranam